Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus MONISTAT 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus MONISTAT 5.
AMPHOTEC vs MONISTAT 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Miconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Miconazole nitrate 100 mg vaginal suppository inserted once daily at bedtime for 3 days; or 200 mg vaginal suppository once daily at bedtime for 3 days; or 1200 mg vaginal suppository as a single dose.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Terminal half-life approximately 24 hours; supports once-daily dosing.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Primarily fecal (90%) as unchanged drug; renal excretion minimal (<1%).
Category C
Category C
Antifungal
Antifungal